Mikhail Shchepinov presenting at Undoing Aging 2019
Mikhail Shchepinov, Chief Scientific Officer at Retrotope, Inc., presenting at Undoing Aging 2019 in Berlin.
More Videos
![](https://www.retrotope.com/wp-content/uploads/2021/05/screen-shot-2021-05-03-at-11.38.56.png)
February 16, 2021
Anil Kumar, Retrotope’s president and chief business officer, gave a corporate presentation as part of the 2021 BIO CEO & Investor Digital Conference. The presentation highlighted a busy year ahead for Retrotope with multiple key data readouts planned for its broad clinical-stage pipeline.
![](https://www.retrotope.com/wp-content/uploads/2021/02/screen-shot-2021-02-02-at-14.44.26.png)
February 1, 2021
A matchstick animation illustrating the concept of the LPO in lipid membranes, and the role of D-PUFAs in inhibiting the chain reaction.
![](https://www.retrotope.com/wp-content/uploads/2021/02/screen-shot-2021-01-05-at-14.19.48-768x432-1.png)
April 21, 2020
Dr. Mark Midei, Retrotope's Chief of Medical Affairs, and Susan Walther, Director of Patient Engagement at Friedreich's Ataxia Research Alliance (FARA), recorded a video about Retrotope’s Friedreich’s ataxia study.
![](https://www.retrotope.com/wp-content/uploads/2021/02/screen-shot-2021-02-10-at-16.04.42.png)
May 17, 2019
Dr. Charles Cantor, co-founder and executive director of Retrotope, Inc., presenting on GoldLab Symposium 2019.
![](https://www.retrotope.com/wp-content/uploads/2021/02/screen-shot-2021-02-10-at-16.10.47.png)
October 18, 2018
Retrotope released new data at the National Organization of Rare Diseases’ Rare Diseases & Orphan Products Breakthrough Summit (NORD Summit) regarding the impact of RT001 on disease progression in 2 patients with infantile neuroaxonal dystrophy (INAD). Dr. Mark Midei discusses what makes RT001 unique.
![](https://www.retrotope.com/wp-content/uploads/2021/02/screen-shot-2021-02-10-at-16.16.09.png)
April 2, 2017
In this 18 minute presentation, Dr. Harry J. Saal, Retrotope’s Chairman, explains to a TEDx audience how Retrotope’s technology impacts the membranes that are frequently damaged in many neurological diseases.
![](https://www.retrotope.com/wp-content/uploads/2021/02/screen-shot-2021-02-10-at-16.21.27.png)
January 25, 2017
A presentation at the Moscow State University by CSO Dr. Misha Shchepinov regarding the mechanism of action of Retrotope's RT001, and its effectiveness in a variety of disease models.